FGF21 and metabolic dysfunction-associated steatohepatitis: Another recently discovered player in the progression from NASH to HCC is fibroblast growth factor 21 (FGF21), which is normally expressed in hepatocytes, reduces fat deposition in the liver and acts as an inflammation suppressor.